<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932058</url>
  </required_header>
  <id_info>
    <org_study_id>PR-OS-001</org_study_id>
    <nct_id>NCT03932058</nct_id>
  </id_info>
  <brief_title>Proteomics Research of Osteosarcoma</brief_title>
  <acronym>PROS001</acronym>
  <official_title>Establishment of New Molecular Prototyping Based on Proteomics for Predicting Osteosarcoma Chemotherapy Response and Risk of Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospectively collected 400 cases of clinical data and pathological paraffin specimens of
      osteosarcoma, chondrosarcoma (control) and endogenous chondroma (control) in our hospital
      from 2008 to 2014, combined with high-pressure cycle-satellite scanning mass spectrometry
      (PCT-SWATH) Molecular typing of osteosarcoma and prediction of targeted therapy, the
      establishment of a new molecular classification based on proteomics for osteosarcoma to
      predict the chemotherapy response and recurrence risk of osteosarcoma. Clinical osteosarcoma
      patients include as many types as possible: pre-chemotherapy, post-chemotherapy, recurrence,
      and metastasis. The study did not involve vulnerable groups, and it was taken as a
      postoperative wax specimen for patients, which had no health, life and other effects on
      patients. Study application exemption from informed consent.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proteomics changes</measure>
    <time_frame>2 years</time_frame>
    <description>Study of changes in proteomes in tumor cells by high-throughput proteomics analysis</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Osteosarcoma</condition>
  <condition>Proteomics</condition>
  <arm_group>
    <arm_group_label>osteosarcoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>chondrosarcoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>enchondroma</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.</description>
    <arm_group_label>osteosarcoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all osteosarcoma patients in our hospital

          -  received Methotrexate+Doxorubicin+Cisplatin protocol chemotherapy

        Exclusion Criteria:

          -  non-chemotherapy patients

          -  bio-specimen not completed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhaoming Ye, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Affiliated Hospital Of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhan Wang, Dr.</last_name>
    <phone>+8618758586092</phone>
    <email>wangzhan515@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaobo Yan</last_name>
    <phone>+8613588153306</phone>
    <email>yanxiaobo82@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2nd Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaobo Yan</last_name>
      <phone>13588153306</phone>
      <email>yanxiaobo82@gmail.com</email>
    </contact>
    <investigator>
      <last_name>zhaoming Ye, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</investigator_affiliation>
    <investigator_full_name>Zhaoming Ye</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

